Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.76 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.61 |
| ▸ | MEN1 | O00255 | 6/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.54 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10020286 | 0.87 | MDM2 (1.00) | MDM2TAAR1KMT2AMEN1RAB9A | |
| SCHEMBL31668740 | 0.85 | MDM2 (0.95) | MDM2TAAR1KMT2AMEN1RAB9A | |
| SCHEMBL4713445 | 0.81 | HTT (0.72) | HTT | |
| SCHEMBL3188517 | 0.81 | GAA (0.75) | KMT2ALMNASMN1; SMN2POLBKDM4E | |
| SCHEMBL3719350 | 0.81 | KDM4E (0.75) | MDM2KMT2AMEN1RAB9ALMNA | |
| SCHEMBL14324708 | 0.80 | RAB9A (0.67) | TAAR1KMT2AMEN1RAB9ALMNA | |
| SCHEMBL751586 | 0.79 | SMN1; SMN2 (0.74) | TAAR1KMT2AMEN1RAB9ALMNA | |
| SCHEMBL23999548 | 0.79 | MDM2 (0.83) | MDM2TAAR1KMT2AMEN1RAB9A | |
| SCHEMBL305498 | 0.79 | TAAR1 (1.00) | MDM2TAAR1KMT2AMEN1RAB9A | |
| SCHEMBL14324384 | 0.78 | MDM2 (0.59) | MDM2TAAR1KMT2AMEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130317027-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-20120329786-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| EP-1248612-B1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-02-27 | — | — | EP | disclosed |
| EP-1248612-A4 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-09-07 | — | — | EP | disclosed |
| US-6525036-B2 | Treating post-menopausal osteoporosis. | MERCK & CO., INC. | 2003-02-25 | — | — | US | disclosed |
| EP-1248612-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2002-10-16 | — | — | EP | disclosed |
| WO-2002070519-A1 | MONOBACTAMS AS CATHEPSIN K INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| US-20020052378-A1 | Novel compounds and compositions as protease inhibitors | Celera Corporation | 2002-05-02 | — | — | US | disclosed |
| WO-2001049288-A9 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001049288-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329786-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | MDM2 2855/4885TAAR1 3129/4885KMT2A 3000/4885 |
| US-20130317027-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | MDM2 2855/4885TAAR1 3129/4885KMT2A 3000/4885 |
| US-20020052378-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, CTRL, SPINT2 | MDM2 1285/4885TAAR1 4628/4885KMT2A 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.